BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 118.54 USD -1.84% Market Closed
Market Cap: 28.6B USD
Have any thoughts about
BioNTech SE?
Write Note

BioNTech SE
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioNTech SE
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
BioNTech SE
NASDAQ:BNTX
Cash Taxes Paid
€482.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cash Taxes Paid
-€1m
CAGR 3-Years
N/A
CAGR 5-Years
-75%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Cash Taxes Paid
€3.9m
CAGR 3-Years
239%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash Taxes Paid
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash Taxes Paid
€11.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Cash Taxes Paid
€166k
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BioNTech SE
Glance View

Market Cap
28.2B USD
Industry
Biotechnology

BioNTech SE, founded in 2008 and headquartered in Mainz, Germany, is a pioneering biotechnology company that has rapidly garnered global attention for its innovative approach to vaccine development and personalized cancer therapies. Originally focused on harnessing the power of messenger RNA (mRNA) technology, BioNTech became a household name following its collaboration with Pfizer to develop one of the first COVID-19 vaccines. This partnership not only showcased the potential of mRNA technology in combatting infectious diseases but also underscored the company’s agility in responding to urgent global health challenges. With its robust pipeline of therapeutics spanning infectious diseases and oncology, BioNTech is positioning itself as a leader in the emerging field of immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively. For investors, BioNTech represents a unique opportunity in the biotech sector, characterized by its strong innovation pipeline, strategic partnerships, and a solid financial footing bolstered by revenues from its COVID-19 vaccine. The company's focus on research and development, with aims to expand its therapeutic offerings beyond infectious diseases to targeted cancer treatments, indicates significant growth potential. Furthermore, as a company driven by science and a commitment to patient-centric solutions, BioNTech is well-positioned to benefit from ongoing advancements in biotechnology and the increasing demand for personalized medicine. With a proven track record and ambitious future aspirations, BioNTech SE offers a compelling narrative for investors looking to capitalize on the transformative potential of biotechnology.

BNTX Intrinsic Value
32.83 USD
Overvaluation 72%
Intrinsic Value
Price

See Also

What is BioNTech SE's Cash Taxes Paid?
Cash Taxes Paid
482.9m EUR

Based on the financial report for Dec 31, 2023, BioNTech SE's Cash Taxes Paid amounts to 482.9m EUR.

What is BioNTech SE's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 1Y
-89%

Over the last year, the Cash Taxes Paid growth was -89%.

Back to Top